Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
If you have any queries or need any help, please contact us at [email protected]
The first GLP-1 receptor agonist was approved for diabetes treatment in 2005
Patrik Jonsson, EVP of Eli Lilly and president of Lilly International, said in an April 30 earnings call that while the company only has a few weeks worth of data from India on how generic semaglutide is impacting the market, it seems the generics are really stimulating the growth in the overall obesity market, and that includes [Mounjaro]. Prescriptions for Mounjaro have been 10% higher in recent weeks compared to before generic semaglutide was introduced, he added
These are brand-asserted statements, not independent rankings, lab-verified claims, or endorsements by this publication
